21 种非转移性癌症患者的长期和短期心血管疾病死亡率。

IF 11.4 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Journal of Advanced Research Pub Date : 2025-03-01 DOI:10.1016/j.jare.2024.03.017

Tianwang Guan , Olivia Monteiro , Dongting Chen , Zehao Luo , Kaiyi Chi , Zhihao Li , Yinglan Liang , Zhenxing Lu , Yanting Jiang , Jinming Yang , Wenrui Lin , Min Yi , Kang Zhang , Caiwen Ou

{"title":"21 种非转移性癌症患者的长期和短期心血管疾病死亡率。","authors":"Tianwang Guan , Olivia Monteiro , Dongting Chen , Zehao Luo , Kaiyi Chi , Zhihao Li , Yinglan Liang , Zhenxing Lu , Yanting Jiang , Jinming Yang , Wenrui Lin , Min Yi , Kang Zhang , Caiwen Ou","doi":"10.1016/j.jare.2024.03.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Previous studies on cardiovascular disease (CVD) death risk in cancer patients mostly focused on overall cancer, age subgroups and single cancers.</div></div><div><h3>Objectives</h3><div>To assess the CVD death risk in non-metastatic cancer patients at 21 cancer sites.</div></div><div><h3>Methods</h3><div>A total of 1,672,561 non-metastatic cancer patients from Surveillance, Epidemiology, and End Results (SEER) datebase (1975–2018) were included in this population-based study, with a median follow-up of 12·7 years. The risk of CVD deaths was assessed using proportions, competing-risk regression, absolute excess risks (AERs), and standardized mortality ratios (SMRs).</div></div><div><h3>Results</h3><div>In patients with localized cancers, the proportion of CVD death and cumulative mortality from CVD in the high-competing risk group (14 of 21 unique cancers) surpassed that of primary neoplasm after cancer diagnosis. The SMRs and AERs of CVD were found higher in patients with non-metastatic cancer than the general US population (SMR 1·96 [95 %CI, 1·95-1·97]–19·85[95 %CI, 16·69-23·44]; AER 5·77–210·48), heart disease (SMR 1·94[95 %CI, 1·93-1·95]–19·25[95 %CI, 15·76-23·29]; AER 4·36–159·10) and cerebrovascular disease (SMR 2·05[95 %CI, 2·02-2·08]–24·71[95 %CI, 16·28-35·96]; AER 1·01–37·44) deaths. In the high-competing risk group, CVD-related SMR in patients with localized stage cancer increased with survival time but followed a reverse-dipper pattern in the low-competing risk group (7 of 21 cancers). The high-competing risk group had higher CVD-related death risks than the low-competing risk group.</div></div><div><h3>Conclusion</h3><div>The CVD death risk in patients with non-metastatic cancer varied by cancer stage, site and survival time. The risk of CVD mortality is higher in 14 out of 21 localized cancers (high-competing cancers). Targeted strategies for CVD management in non-metastatic cancer patients are needed.</div></div>","PeriodicalId":14952,"journal":{"name":"Journal of Advanced Research","volume":"69 ","pages":"Pages 215-224"},"PeriodicalIF":11.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term and short-term cardiovascular disease mortality among patients of 21 non-metastatic cancers\",\"authors\":\"Tianwang Guan , Olivia Monteiro , Dongting Chen , Zehao Luo , Kaiyi Chi , Zhihao Li , Yinglan Liang , Zhenxing Lu , Yanting Jiang , Jinming Yang , Wenrui Lin , Min Yi , Kang Zhang , Caiwen Ou\",\"doi\":\"10.1016/j.jare.2024.03.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Previous studies on cardiovascular disease (CVD) death risk in cancer patients mostly focused on overall cancer, age subgroups and single cancers.</div></div><div><h3>Objectives</h3><div>To assess the CVD death risk in non-metastatic cancer patients at 21 cancer sites.</div></div><div><h3>Methods</h3><div>A total of 1,672,561 non-metastatic cancer patients from Surveillance, Epidemiology, and End Results (SEER) datebase (1975–2018) were included in this population-based study, with a median follow-up of 12·7 years. The risk of CVD deaths was assessed using proportions, competing-risk regression, absolute excess risks (AERs), and standardized mortality ratios (SMRs).</div></div><div><h3>Results</h3><div>In patients with localized cancers, the proportion of CVD death and cumulative mortality from CVD in the high-competing risk group (14 of 21 unique cancers) surpassed that of primary neoplasm after cancer diagnosis. The SMRs and AERs of CVD were found higher in patients with non-metastatic cancer than the general US population (SMR 1·96 [95 %CI, 1·95-1·97]–19·85[95 %CI, 16·69-23·44]; AER 5·77–210·48), heart disease (SMR 1·94[95 %CI, 1·93-1·95]–19·25[95 %CI, 15·76-23·29]; AER 4·36–159·10) and cerebrovascular disease (SMR 2·05[95 %CI, 2·02-2·08]–24·71[95 %CI, 16·28-35·96]; AER 1·01–37·44) deaths. In the high-competing risk group, CVD-related SMR in patients with localized stage cancer increased with survival time but followed a reverse-dipper pattern in the low-competing risk group (7 of 21 cancers). The high-competing risk group had higher CVD-related death risks than the low-competing risk group.</div></div><div><h3>Conclusion</h3><div>The CVD death risk in patients with non-metastatic cancer varied by cancer stage, site and survival time. The risk of CVD mortality is higher in 14 out of 21 localized cancers (high-competing cancers). Targeted strategies for CVD management in non-metastatic cancer patients are needed.</div></div>\",\"PeriodicalId\":14952,\"journal\":{\"name\":\"Journal of Advanced Research\",\"volume\":\"69 \",\"pages\":\"Pages 215-224\"},\"PeriodicalIF\":11.4000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Advanced Research\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2090123224001176\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advanced Research","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2090123224001176","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

导言：以往关于癌症患者心血管疾病（CVD）死亡风险的研究大多集中在整体癌症、年龄亚组和单一癌症：以往关于癌症患者心血管疾病（CVD）死亡风险的研究大多集中在整体癌症、年龄亚组和单一癌症上：评估 21 个癌症部位的非转移性癌症患者的心血管疾病死亡风险：这项基于人群的研究共纳入了 1,672,561 名来自监测、流行病学和最终结果（SEER）（1975-2018 年）的非转移性癌症患者，中位随访时间为 12-7 年。研究采用比例、竞争风险回归、绝对超额风险（AER）和标准化死亡率（SMR）对心血管疾病死亡风险进行了评估：结果：在局部癌症患者中，高竞争风险组（21种独特癌症中的14种）的心血管疾病死亡比例和心血管疾病累积死亡率超过了癌症诊断后原发肿瘤的比例。非转移性癌症患者的心血管疾病SMR和AER高于美国普通人群（SMR 1-96 [95 %CI, 1-95-1-97]-19-85[95 %CI, 16-69-23-44]；AER：5-77-210-48）、心脏病（SMR：1-94[95 %CI，1-93-1-95]-19-25[95 %CI，15-76-23-29]；AER：4-36-159-10）和脑血管疾病（SMR：2-05[95 %CI，2-02-2-08]-24-71[95 %CI，16-28-35-96]；AER：1-01-37-44）死亡。在高竞争风险组中，局部分期癌症患者与心血管疾病相关的SMR随生存时间的延长而增加，但在低竞争风险组（21种癌症中的7种）中却呈现出相反的下降模式。高竞争风险组与心血管疾病相关的死亡风险高于低竞争风险组：结论：非转移性癌症患者的心血管疾病死亡风险因癌症分期、部位和生存时间而异。在21种局部癌症（高竞争癌症）中，14种癌症的心血管疾病死亡风险较高。需要对非转移性癌症患者的心血管疾病采取有针对性的管理策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Long-term and short-term cardiovascular disease mortality among patients of 21 non-metastatic cancers

查看原文本刊更多论文

Long-term and short-term cardiovascular disease mortality among patients of 21 non-metastatic cancers

Introduction

Previous studies on cardiovascular disease (CVD) death risk in cancer patients mostly focused on overall cancer, age subgroups and single cancers.

Objectives

To assess the CVD death risk in non-metastatic cancer patients at 21 cancer sites.

Methods

A total of 1,672,561 non-metastatic cancer patients from Surveillance, Epidemiology, and End Results (SEER) datebase (1975–2018) were included in this population-based study, with a median follow-up of 12·7 years. The risk of CVD deaths was assessed using proportions, competing-risk regression, absolute excess risks (AERs), and standardized mortality ratios (SMRs).

Results

In patients with localized cancers, the proportion of CVD death and cumulative mortality from CVD in the high-competing risk group (14 of 21 unique cancers) surpassed that of primary neoplasm after cancer diagnosis. The SMRs and AERs of CVD were found higher in patients with non-metastatic cancer than the general US population (SMR 1·96 [95 %CI, 1·95-1·97]–19·85[95 %CI, 16·69-23·44]; AER 5·77–210·48), heart disease (SMR 1·94[95 %CI, 1·93-1·95]–19·25[95 %CI, 15·76-23·29]; AER 4·36–159·10) and cerebrovascular disease (SMR 2·05[95 %CI, 2·02-2·08]–24·71[95 %CI, 16·28-35·96]; AER 1·01–37·44) deaths. In the high-competing risk group, CVD-related SMR in patients with localized stage cancer increased with survival time but followed a reverse-dipper pattern in the low-competing risk group (7 of 21 cancers). The high-competing risk group had higher CVD-related death risks than the low-competing risk group.

Conclusion

The CVD death risk in patients with non-metastatic cancer varied by cancer stage, site and survival time. The risk of CVD mortality is higher in 14 out of 21 localized cancers (high-competing cancers). Targeted strategies for CVD management in non-metastatic cancer patients are needed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Advanced Research Multidisciplinary-Multidisciplinary

CiteScore

21.60

自引率

0.90%

发文量

280

审稿时长

12 weeks

期刊介绍： Journal of Advanced Research (J. Adv. Res.) is an applied/natural sciences, peer-reviewed journal that focuses on interdisciplinary research. The journal aims to contribute to applied research and knowledge worldwide through the publication of original and high-quality research articles in the fields of Medicine, Pharmaceutical Sciences, Dentistry, Physical Therapy, Veterinary Medicine, and Basic and Biological Sciences. The following abstracting and indexing services cover the Journal of Advanced Research: PubMed/Medline, Essential Science Indicators, Web of Science, Scopus, PubMed Central, PubMed, Science Citation Index Expanded, Directory of Open Access Journals (DOAJ), and INSPEC.